TD Cowen Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) Stock

Posted by Brenda Bartman on Nov 10th, 2026

Zymeworks (NASDAQ:ZYME – Get Free Report) had its price target increased by analysts at TD Cowen from $34.00 to $39.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen‘s price target suggests a potential upside of 24.39% from the company’s previous close.

A number of other research firms have also recently commented on ZYME. JPMorgan Chase & Co. boosted their price target on shares of Zymeworks from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, September 3rd. Citigroup restated a “market outperform” rating on shares of Zymeworks in a research report on Monday, October 26th. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on shares of Zymeworks in a report on Wednesday, August 26th. HC Wainwright upped their target price on shares of Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Stifel Nicolaus set a $46.00 target price on Zymeworks in a research note on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zymeworks has an average rating of “Moderate Buy” and a consensus price target of $42.25.

Check Out Our Latest Analysis on ZYME

Zymeworks Trading Up 1.8%

Shares of NASDAQ ZYME traded up $0.54 during midday trading on Tuesday, hitting $31.35. 565,503 shares of the company’s stock were exchanged, compared to its average volume of 778,225. Zymeworks has a 12-month low of $18.20 and a 12-month high of $31.97. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -15.54 and a beta of 1.32. The business’s fifty day moving average price is $27.46 and its two-hundred day moving average price is $25.38.

Zymeworks (NASDAQ:ZYME – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.01. The company had revenue of $512.92 million for the quarter, compared to analysts’ expectations of $227.40 million. Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. Zymeworks’s revenue for the quarter was up 828.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.26) earnings per share. Equities analysts expect that Zymeworks will post 1.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zymeworks news, EVP Adam Schayowitz sold 13,832 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the sale, the executive vice president owned 23,205 shares of the company’s stock, valued at $599,849.25. This represents a 37.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is owned by insiders.

Institutional Investors Weigh In On Zymeworks

Hedge funds have recently made changes to their positions in the business. Fisher Asset Management LLC lifted its position in Zymeworks by 759.9% during the third quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock valued at $16,122,000 after purchasing an additional 537,837 shares in the last quarter. Russell Investments Group Ltd. increased its position in Zymeworks by 104.7% in the third quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company’s stock worth $2,596,000 after buying an additional 50,127 shares in the last quarter. Calamos Advisors LLC purchased a new stake in Zymeworks in the third quarter worth about $1,232,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Zymeworks in the third quarter worth about $96,000. Finally, ProShare Advisors LLC raised its stake in shares of Zymeworks by 91.5% in the third quarter. ProShare Advisors LLC now owns 16,390 shares of the company’s stock worth $434,000 after buying an additional 7,833 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Key Stories Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

Positive Sentiment: HC Wainwright raised its price target to $56 from $55 and maintained a Buy rating, signaling substantial potential upside in the analyst’s view. Tickerreport article
Positive Sentiment: Zymeworks raised its 2026 earnings guidance, a favorable update for the company’s near-term outlook. 2026 earnings guidance article
Neutral Sentiment: Q3 results showed a sharp swing to profit, with EPS of $2.28 versus a loss a year earlier. Revenue was reported above estimates. A $250 million milestone payment from Jazz Pharmaceuticals contributed to the profit, so investors may view some of the results as nonrecurring. Milestone and earnings article
Negative Sentiment: EPS beat one cited consensus estimate of $2.27 by a penny, but missed the Zacks estimate of $2.40, leaving the earnings comparison mixed. Zacks earnings article

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.